Key facts
- Cellura’s last known valuation is $4.4M (Oct 2025).
- It has raised $1.5M; the latest was Seed Round ($1.4M) in Oct 2025.
- Notable investors include Bpifrance, Angel's Bay Invest, Incubateur Impulse, Seed for Good.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Cellura
- ·The full record, as it builds
Funding rounds
No funding rounds for Cellura are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cellura
Developer of bioreactor systems designed for industrial-scale cell expansion and bioproduction. The company's platform features a geo-inspired rotating vessel that achieves homogeneous mixing, minimal shear stress, seamless scale-up from research to production volumes, and compatibility with delicate cell types such as stem cells, organoids, immune cells, and microalgae, enabling cell-therapy developers and biotech manufacturers to streamline culturing of sensitive cells while maintaining viability and reproducibility.
- Sector
- Healthcare
- HQ
- Marseille, France
- Founded
- 2022
- Employees
- 3
- Website
- cellura.io/
- Ownership
- Privately Held (backing)
Cellura doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cellura shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cellura in its N-PORT filings yet. We sweep new filings monthly.